NCT00169611
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +14 more
- Locations
-
- Laurence LION-FRANCOIS Lyon, France
Clinical trial condition
Neurofibromatosis 1
Explore clinical trials studying Neurofibromatosis 1. Study availability and eligibility vary by location and protocol.
133 public trials
21 recruiting studies
Neurofibromatosis 1 trial results
Active, Not Recruiting
Natural History Study of Patients With Neurofibromatosis Type I
NCT00924196
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cranial Nerve Diseases, Cranial Nerve Neoplasms, +38 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Active, Not Recruiting
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
NCT01362803
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +22 more
- Locations
-
- Children's National Medical Center Washington D.C., District of Columbia, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
NCT03190915
- Conditions
- Bone Marrow Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +22 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
- Arkansas Children's Hospital Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center Downey, California, United States
Active, Not Recruiting
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
NCT06262113
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +13 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States
Active, Not Recruiting
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
NCT03962543
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +18 more
- Locations
-
- University of Alabama at Birmingham/Children's of Alabama Birmingham, Alabama, United States
- Mayo Clinic Arizona Phoenix, Arizona, United States
- Arkansas Children's Hospital Little Rock, Arkansas, United States
- Children's Hospital Los Angeles Los Angeles, California, United States
Active, Not Recruiting
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ganglioglioma, Anaplastic Oligodendroglioma, +62 more
- Locations
-
- Phoenix Children s Hospital Phoenix, Arizona, United States
- Childrens National Hospital Washington D.C., District of Columbia, United States
- Nicklaus Childrens Hospital Miami, Florida, United States
- Indiana Uni School of Medicine Indianapolis, Indiana, United States
Active, Not Recruiting
Interventions for Reading Disabilities in NF1
NCT02964884
- Conditions
- Communication Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslexia, +28 more
- Locations
-
- Vanderbilt University Nashville, Tennessee, United States
Active, Not Recruiting
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +16 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
- Arkansas Children's Hospital Little Rock, Arkansas, United States
Active, Not Recruiting
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
NCT05309668
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +14 more
- Locations
-
- Research Site Akron, Ohio, United States
- Research Site Philadelphia, Pennsylvania, United States
- Research Site Houston, Texas, United States
- Research Site Richmond, Virginia, United States
Related conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities (133)
- Heredodegenerative Disorders, Nervous System (133)
- Neoplasms by Histologic Type (133)
- Neoplasms, Nerve Tissue (133)
- Neoplastic Syndromes, Hereditary (133)
- Nervous System Diseases (133)
- Neurodegenerative Diseases (133)
- Neuromuscular Diseases (133)